Genmab — Oktober 2017
-
The alliances are focused on three key areas: infectious diseases including HIV, respiratory illnesses such respiratory syncytial virus (RSV), and infections acquired in health facilities like hospital-acquired flu. In addition to the research deals, Vir has also acquired Humabs BioMed, a Swiss company that’s developing more than 15 antibodies to treat diseases ranging from Zika to hepatitis B
-
Men vi har jo ikke rigtig set resultater af dara+pom label expansion i omsætningen endnu
-
Spændende virksomhed. Og sikke perspektiver!
-
Der er en del, der har efterlyst forklaringer. At udlægge det som negativitet giver ingen mening
-
Jeg har allerede budt ind med 81-82m svarende til 4,1m Per klinikdag
-
-
Ja. Tallene for juli var en stor skuffelse. Jeg havde regnet med effekt fra dara+pom, men den udeblev
-
-
Overall, in the third-line setting, DARZALEX-containing regimes are now about 1/3 of market share. And that's very close to -- very similar to the market share of REVLIMID. So each month, it's sort of down at the beginning to sort of swap over. REVLIMID gets the most 1 month. DARZALEX, the next. So they're pretty equal at about 1/3 each. Also seeing in the third-line, as you would expect, that the combinations -- DARZALEX combinations are used more than the DARZALEX monotherapy in that third-lin
-
Sukker. Det er jeg helt med på - jeg hentyder til label expansion med pom, der kom medio juni. Den skulle gerne vise effekt oven på din beskrivelse. Måske endda off label siden vi taler US
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind